# EAA172 (NCT03701321)

> Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03701321
- Phase: PHASE1, PHASE2
- Status: WITHDRAWN
- Sponsor: National Cancer Institute (NCI)
- Conditions: Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
- Interventions: Bortezomib; Daratumumab; Dexamethasone; Venetoclax
- Enrollment: 0
- Primary outcome: Maximum tolerated dose of venetoclax in combination with daratumumab, bortezomib and dexamethasone (Phase I)
- Primary outcome: Minimal residual disease (MRD) negative status (Phase II)

## Indexed commentary on EAA172 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=eaa172-nct03701321